Close Menu

Memorial Sloan-Kettering

Researchers saw abbreviated overall survival times in estrogen receptor-positive metastatic breast cancer patients with ESR1 mutations in their cell-free DNA.

Immunotherapy Buzz

The New York Times looks at immunotherapy and its use in cancer treatment.

In a cohort of more than 150 patients, none who responded well to anti-androgen therapy had AR-V7-positive circulating tumor cells detected by Epic's technology.

The partners will focus on microbiome drugs for cancer patients undergoing hematopoietic stem cell transplantation or receiving checkpoint inhibitors.

Some 20 percent of 650 clinical germlines analyzed since the project launched last year have had at least one variant associated with increased cancer risk.

The institute will combine expertise from six cancer centers in the US in order to drive research and drug development in cancer immunotherapy. 

The data included results from thousands of clinically tested samples showing frequent identification of clinically useful diagnostic and prognostic markers.

The partners will evaluate the ability of ImmunID's ImmunTracker assay to predict the responses of patients with solid tumors to cancer immunotherapy.

Two separate studies concluded that in most SEO cancer cases what they are seeing are two separate early-stage tumors, instead of late-stage cancer.

Sage is handling the initial data processing and cleaning for the consortium, while MSKCC is providing infrastructure for hosting the data.

Pages

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.